You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenzphetamine
Accession NumberDB00865  (APRD00759)
TypeSmall Molecule
GroupsApproved, Illicit
Description

A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

Structure
Thumb
Synonyms
(+)-benzphetamine
(+)-N-Benzyl-N,alpha-dimethylphenethylamine
(+)-N-benzyl-N,α-dimethylphenethylamine
(+)-N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine
(+)-N,α-dimethyl-N-(phenylmethyl)-benzeneethanamine
(AlphaS)-N,alpha-dimethylphenethylamine
(S)-(+)-benzphetamine
(S)-(+)-N-Benzyl-N,alpha-dimethylphenethylamine
(S)-(+)-N-benzyl-N,α-dimethylphenethylamine
(S)-benzphetamine
Benzaphetamine
Benzfetamina
Benzfetamine
Benzfetaminum
Benzphetamine
Benzylamphetamine
D-N-Methyl-N-benzyl-beta-phenylisopropylamine
d-N-methyl-N-benzyl-β-phenylisopropylamine
N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Didrextablet50 mg/1oralA S Medication Solutions Llc1960-10-26Not applicableUs
Didrextablet50 mg/1oralPharmacia and Upjohn Company1960-10-262015-12-29Us
Didrextablet50 mg/1oralPd Rx Pharmaceuticals, Inc.1960-10-26Not applicableUs
Didrextablet50 mg/1oralA S Medication Solutions Llc1960-10-26Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benzphetaminetablet25 mg/1oralTedor Pharma Inc.2016-02-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-09Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2008-12-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralBoca Pharmacal, LLC2010-09-07Not applicableUs
Benzphetamine Hydrochloridetablet, film coated50 mg/1oralEpic Pharma, LLC2015-12-16Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralAidarex Pharmaceuticals LLC2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet, film coated50 mg/1oralHeritage Pharmaceuticals Inc.2012-10-19Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralMikart, Inc.2011-11-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralApotheca Inc.2009-12-09Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralNivagen Pharmaceuticals, Inc.2016-01-15Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralSolco Healthcare US LLC2011-08-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralKvk Tech, Inc2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet25 mg/1oralNivagen Pharmaceuticals, Inc.2016-01-15Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralbryant ranch prepack2010-02-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralC.O. Truxton, Inc.2011-11-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2011-11-01Not applicableUs
Regimextablet25 mg/1oralWraser Pharmaceuticals2013-02-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Benzphetamine Hydrochloride
Thumb
  • InChI Key: ANFSNXAXVLRZCG-UHFFFAOYNA-N
  • Monoisotopic Mass: 275.144077416
  • Average Mass: 275.816
DBSALT000832
Categories
UNII0M3S43XK27
CAS number156-08-1
WeightAverage: 239.3553
Monoisotopic: 239.167399677
Chemical FormulaC17H21N
InChI KeyInChIKey=YXKTVDFXDRQTKV-HNNXBMFYSA-N
InChI
InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
IUPAC Name
benzyl(methyl)[(2S)-1-phenylpropan-2-yl]amine
SMILES
C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
PharmacodynamicsBenzphetamine, a phenylalkylamin, is related to amphetamine both chemically and pharmacologically. It is an anorectic agent indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Mechanism of actionAlthough the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors.
Related Articles
AbsorptionReadily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.
Volume of distributionNot Available
Protein binding75-99%
Metabolism

Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine.

SubstrateEnzymesProduct
Benzphetamine
Not Available
AmphetamineDetails
Benzphetamine
Not Available
MethamphetamineDetails
Route of eliminationNot Available
Half life16 to 31 hours
ClearanceNot Available
ToxicityLD50=160 mg/kg (orally in rats). Acute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9864
Caco-2 permeable+0.8815
P-glycoprotein substrateSubstrate0.541
P-glycoprotein inhibitor INon-inhibitor0.8803
P-glycoprotein inhibitor IINon-inhibitor0.9437
Renal organic cation transporterInhibitor0.7013
CYP450 2C9 substrateNon-substrate0.769
CYP450 2D6 substrateNon-substrate0.588
CYP450 3A4 substrateNon-substrate0.5135
CYP450 1A2 substrateInhibitor0.8684
CYP450 2C9 inhibitorNon-inhibitor0.9146
CYP450 2D6 inhibitorInhibitor0.539
CYP450 2C19 inhibitorNon-inhibitor0.5997
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8047
Ames testNon AMES toxic0.888
CarcinogenicityNon-carcinogens0.6584
BiodegradationNot ready biodegradable0.9825
Rat acute toxicity3.1442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8779
hERG inhibition (predictor II)Non-inhibitor0.5331
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Corepharma llc
  • Impax laboratories inc
  • Kvk tech inc
  • Paddock laboratories inc
  • Tedor pharma inc
  • Tyco healthcare mallinckrodt
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Tabletoral50 mg/1
Tablet, film coatedoral50 mg/1
Tabletoral25 mg/1
Prices
Unit descriptionCostUnit
Didrex 50 mg tablet1.71USD tablet
Benzphetamine hcl 50 mg tablet1.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129-130Heinzelman, R.V. and Aspergren, B.D.; US. Patent 2,789,138; April 16,1957; assigned to The Upjohn Company.
water solubilityReadily solubleNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0233 mg/mLALOGPS
logP3.72ALOGPS
logP4.34ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity78.39 m3·mol-1ChemAxon
Polarizability29.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.86 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Dennis J. Kalota, Keith G. Tomazi, “Crystallization Method for Benzphetamine.” U.S. Patent US20080262268, issued October 23, 2008.

US20080262268
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (16.6 KB)
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Benzphetamine.
AcepromazineAcepromazine may decrease the stimulatory activities of Benzphetamine.
AcetaminophenThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Acetaminophen.
AcetazolamideAcetazolamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Benzphetamine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Acetylsalicylic acid.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AminophyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Aminophylline.
AmisulprideAmisulpride may decrease the stimulatory activities of Benzphetamine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Benzphetamine.
Ammonium chlorideThe serum concentration of Benzphetamine can be decreased when it is combined with Ammonium chloride.
AmphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Amphetamine.
AprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Aprepitant.
ArformoterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Arformoterol.
AripiprazoleAripiprazole may decrease the stimulatory activities of Benzphetamine.
ArmodafinilThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Articaine.
AtomoxetineAtomoxetine may increase the hypertensive activities of Benzphetamine.
BenzquinamideBenzquinamide may decrease the stimulatory activities of Benzphetamine.
BexaroteneThe serum concentration of Benzphetamine can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Benzphetamine can be decreased when it is combined with Bosentan.
BrompheniramineBenzphetamine may decrease the sedative activities of Brompheniramine.
ButalbitalThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Butalbital.
CaffeineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Caffeine.
Calcium AcetateCalcium Acetate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
CarphenazineCarphenazine may decrease the stimulatory activities of Benzphetamine.
ChlormezanoneChlormezanone may decrease the stimulatory activities of Benzphetamine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Benzphetamine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Benzphetamine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Benzphetamine.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Benzphetamine.
ClozapineClozapine may decrease the stimulatory activities of Benzphetamine.
CocaineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Cocaine.
ConivaptanThe serum concentration of Benzphetamine can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dexmethylphenidate.
DextroamphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dextroamphetamine.
DiclofenamideDiclofenamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
DiethylpropionThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Diethylpropion.
DihydrocodeineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dihydrocodeine.
DipivefrinThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dipivefrin.
DobutamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dobutamine.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Benzphetamine.
DoxapramThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Doxapram.
DoxofyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Benzphetamine.
DroperidolDroperidol may decrease the stimulatory activities of Benzphetamine.
DyphyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dyphylline.
EphedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ephedrine.
EpinephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Epinephrine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
FencamfamineFencamfamine may decrease the stimulatory activities of Benzphetamine.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Benzphetamine.
FluconazoleThe metabolism of Benzphetamine can be decreased when combined with Fluconazole.
FlupentixolFlupentixol may decrease the stimulatory activities of Benzphetamine.
FluphenazineFluphenazine may decrease the stimulatory activities of Benzphetamine.
FluspirileneFluspirilene may decrease the stimulatory activities of Benzphetamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Fluticasone Propionate.
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Benzphetamine.
FosaprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Benzphetamine can be increased when it is combined with Fusidic Acid.
HaloperidolHaloperidol may decrease the stimulatory activities of Benzphetamine.
HexamethylenetetramineThe serum concentration of Benzphetamine can be decreased when it is combined with Hexamethylenetetramine.
IdelalisibThe serum concentration of Benzphetamine can be increased when it is combined with Idelalisib.
IndacaterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Indacaterol.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Benzphetamine.
Ioflupane I 123Benzphetamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ipratropium bromide.
IsomethepteneThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Benzphetamine.
IvacaftorThe serum concentration of Benzphetamine can be increased when it is combined with Ivacaftor.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Benzphetamine.
LevonordefrinThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Levonordefrin.
LinezolidLinezolid may increase the hypertensive activities of Benzphetamine.
LisdexamfetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Lisdexamfetamine.
LithiumLithium may decrease the stimulatory activities of Benzphetamine.
LoxapineLoxapine may decrease the stimulatory activities of Benzphetamine.
LuliconazoleThe serum concentration of Benzphetamine can be increased when it is combined with Luliconazole.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Benzphetamine.
MepivacaineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mepivacaine.
MesoridazineMesoridazine may decrease the stimulatory activities of Benzphetamine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Benzphetamine.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Benzphetamine.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Benzphetamine.
MethylphenidateThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methylphenidate.
MidodrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Midodrine.
MifepristoneThe serum concentration of Benzphetamine can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Benzphetamine can be decreased when it is combined with Mitotane.
ModafinilThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Modafinil.
MolindoneMolindone may decrease the stimulatory activities of Benzphetamine.
MorphineBenzphetamine may increase the analgesic activities of Morphine.
NabiloneNabilone may increase the tachycardic activities of Benzphetamine.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Benzphetamine.
NelfinavirThe metabolism of Benzphetamine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Benzphetamine can be increased when it is combined with Netupitant.
NorepinephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Norepinephrine.
OlanzapineOlanzapine may decrease the stimulatory activities of Benzphetamine.
OlodaterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Olodaterol.
OndansetronOndansetron may decrease the stimulatory activities of Benzphetamine.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Benzphetamine.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Benzphetamine.
PalbociclibThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may decrease the stimulatory activities of Benzphetamine.
PerphenazinePerphenazine may decrease the stimulatory activities of Benzphetamine.
PhendimetrazineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Phendimetrazine.
PhenelzinePhenelzine may increase the hypertensive activities of Benzphetamine.
PheniramineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pheniramine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Benzphetamine.
PhentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Phentermine.
PhenylephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Benzphetamine.
PhenytoinThe metabolism of Benzphetamine can be increased when combined with Phenytoin.
PimozidePimozide may decrease the stimulatory activities of Benzphetamine.
PiperacetazinePiperacetazine may decrease the stimulatory activities of Benzphetamine.
PirbuterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pirbuterol.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Benzphetamine.
PromazinePromazine may decrease the stimulatory activities of Benzphetamine.
PropylhexedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Propylhexedrine.
PseudoephedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pseudoephedrine.
QuetiapineQuetiapine may decrease the stimulatory activities of Benzphetamine.
RacepinephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Racepinephrine.
RemoxiprideRemoxipride may decrease the stimulatory activities of Benzphetamine.
ReserpineReserpine may decrease the stimulatory activities of Benzphetamine.
RisperidoneRisperidone may decrease the stimulatory activities of Benzphetamine.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Benzphetamine.
SalbutamolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Benzphetamine.
SertindoleSertindole may decrease the stimulatory activities of Benzphetamine.
SiltuximabThe serum concentration of Benzphetamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Benzphetamine can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Benzphetamine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Benzphetamine can be increased when it is combined with Stiripentol.
SulpirideSulpiride may decrease the stimulatory activities of Benzphetamine.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Benzphetamine.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Benzphetamine.
TheophyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Theophylline.
ThioridazineThioridazine may decrease the stimulatory activities of Benzphetamine.
ThiothixeneThiothixene may decrease the stimulatory activities of Benzphetamine.
TocilizumabThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.
TranylcypromineTranylcypromine may increase the hypertensive activities of Benzphetamine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Benzphetamine.
TriprolidineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Triprolidine.
VilanterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Vilanterol.
Vitamin CThe serum concentration of Benzphetamine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Benzphetamine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Benzphetamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613 ]
  2. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22. [PubMed:15728379 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA: Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. [PubMed:8486332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Bumpus NN, Sridar C, Kent UM, Hollenberg PF: The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos. 2005 Jun;33(6):795-802. Epub 2005 Mar 15. [PubMed:15769884 ]
  2. Shebley M, Kent UM, Ballou DP, Hollenberg PF: Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52. doi: 10.1124/dmd.108.024661. Epub 2009 Jan 14. [PubMed:19144770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Molecular Weight:
76689.12 Da
References
  1. Kanaeva IP, Nikityuk OV, Davydov DR, Dedinskii IR, Koen YM, Kuznetsova GP, Skotselyas ED, Bachmanova GI, Archakov AI: Comparative study of monomeric reconstituted and membrane microsomal monooxygenase systems of the rabbit liver. II. Kinetic parameters of reductase and monooxygenase reactions. Arch Biochem Biophys. 1992 Nov 1;298(2):403-12. [PubMed:1416971 ]
  2. Matsumoto T, Emi Y, Kawabata S, Omura T: Purification and characterization of three male-specific and one female-specific forms of cytochrome P-450 from rat liver microsomes. J Biochem. 1986 Nov;100(5):1359-71. [PubMed:2434473 ]
  3. Kojima H, Takahashi K, Sakane F, Koyama J: Purification and characterization of NADPH-cytochrome c reductase from porcine polymorphonuclear leukocytes. J Biochem. 1987 Nov;102(5):1083-8. [PubMed:3125159 ]
  4. Dutton DR, McMillen SK, Parkinson A: Purification of rat liver microsomal cytochrome P-450b without the use of nonionic detergent. J Biochem Toxicol. 1988 Summer;3:131-45. [PubMed:3148724 ]
  5. Halpert JR, Miller NE, Gorsky LD: On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403. [PubMed:3924914 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23